ReviewFrontiers in immunology2026
Cellular senescence in Crohn's disease: a double-edged sword in intestinal fibrosis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence represents a pivotal yet paradoxical determinant in the pathogenesis of intestinal fibrosis associated with Crohn's disease (CD). While acute senescence may facilitate tissue repair and limit fibrogenesis, the chronic accumulation of senescent cells drives persistent inflammation and excessive extracellular matrix (ECM) deposition, ultimately leading to irreversible fibrotic strictures. This review systematically delineates the triggers of cellular senescence within the CD microenvironment-including oxidative stress, telomere dysfunction, endoplasmic reticulum stress, and genotoxic damage-and elucidates the roles of diverse senescent cell types (myo-/fibroblasts, endothelial, epithelial, and immune cells) in fibrotic progression. Central to this process is the senescence-associated secretory phenotype (SASP), which acts as a core mediator linking senescence to fibrosis through paracrine activation, ECM imbalance, immune modulation, and stem cell dysfunction. We further discuss emerging therapeutic strategies targeting senescent cells, such as senolytics and senomorphics, and highlight the translational potential of senescence-directed interventions in mitigating intestinal fibrosis. Understanding the dual roles of cellular senescence offers novel insights into the mechanisms of CD-related fibrogenesis and paves the way for innovative antifibrotic therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.